These actions incorporate class-huge basic safety labeling adjustments and new publish-internet marketing requirements for all ER/LA opioid analgesics. FDA also responded to 2 citizen petitions relating to labeling of opioids.  March:  FDA satisfied with makers of ER/LA opioid discomfor